Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk …
JH Ishida, A Patel, AK Mehta, P Gatault… - Antimicrobial agents …, 2017 - Am Soc Microbiol
Cytomegalovirus (CMV) infection is a significant complication after kidney transplantation.
We examined the ability of RG7667, a combination of two monoclonal antibodies, to prevent …
We examined the ability of RG7667, a combination of two monoclonal antibodies, to prevent …
[HTML][HTML] Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in …
JH Ishida, A Patel, AK Mehta, P Gatault… - Antimicrobial Agents …, 2017 - ncbi.nlm.nih.gov
Cytomegalovirus (CMV) infection is a significant complication after kidney transplantation.
We examined the ability of RG7667, a combination of two monoclonal antibodies, to prevent …
We examined the ability of RG7667, a combination of two monoclonal antibodies, to prevent …
Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk …
JH Ishida, AP Anita Patel, AK Mehta, P Gatault… - 2017 - cabidigitallibrary.org
Cytomegalovirus (CMV) infection is a significant complication after kidney transplantation.
We examined the ability of RG7667, a combination of two monoclonal antibodies, to prevent …
We examined the ability of RG7667, a combination of two monoclonal antibodies, to prevent …
Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High …
JH Ishida, A Patel, AK Mehta… - Antimicrobial …, 2017 - scholarlycommons.henryford.com
Cytomegalovirus (CMV) infection is a significant complication after kidney transplantation.
We examined the ability of RG7667, a combination of two monoclonal antibodies, to prevent …
We examined the ability of RG7667, a combination of two monoclonal antibodies, to prevent …
Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High …
JH Ishida, A Patel, AK Mehta… - Antimicrobial …, 2017 - pubmed.ncbi.nlm.nih.gov
Cytomegalovirus (CMV) infection is a significant complication after kidney transplantation.
We examined the ability of RG7667, a combination of two monoclonal antibodies, to prevent …
We examined the ability of RG7667, a combination of two monoclonal antibodies, to prevent …
Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High …
JH Ishida, A Patel, AK Mehta, P Gatault… - Antimicrobial Agents …, 2017 - europepmc.org
Cytomegalovirus (CMV) infection is a significant complication after kidney transplantation.
We examined the ability of RG7667, a combination of two monoclonal antibodies, to prevent …
We examined the ability of RG7667, a combination of two monoclonal antibodies, to prevent …
Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High …
JH Ishida, A Patel, AK Mehta, P Gatault… - Antimicrobial Agents …, 2017 - europepmc.org
Cytomegalovirus (CMV) infection is a significant complication after kidney transplantation.
We examined the ability of RG7667, a combination of two monoclonal antibodies, to prevent …
We examined the ability of RG7667, a combination of two monoclonal antibodies, to prevent …